ELECTROCORE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.65 USD | +0.18% |
|
-1.57% | -5.07% |
| Apr. 08 | ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness | CI |
| Mar. 13 | ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 23.94M | Sales 2025 * | 34.71M | Capitalization | 33.91M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M | Net income 2025 * | -7M | EV / Sales 2024 * | 1.42 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.98 x |
| P/E ratio 2024 * |
-3.13
x | P/E ratio 2025 * |
-5.62
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on electroCore, Inc.
More recommendations
More press releases
| 1 day | +0.18% | ||
| 1 week | -1.57% | ||
| Current month | -8.43% | ||
| 1 month | -18.47% | ||
| 3 months | -14.78% | ||
| 6 months | -1.91% | ||
| Current year | -5.07% |
1 week
5.32
6.34
1 month
5.326.77
Current year
5.328.08
1 year
3.838.08
3 years
2.9329.55
5 years
2.9396.90
10 years
2.93303.75
| Managers | Title | Age | Since |
|---|---|---|---|
Peter S. Staats
FOU | Founder | 61 | 05-08-31 |
| Chief Executive Officer | 65 | 19-09-30 | |
Brian Posner
DFI | Director of Finance/CFO | 62 | 19-03-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Gandolfo
BRD | Director/Board Member | 63 | 20-04-01 |
| Chief Executive Officer | 65 | 19-09-30 | |
F. Cuneo
CHM | Chairman | 80 | 20-04-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5.65 | +0.18% | 7,408 |
| 24-04-18 | 5.64 | +0.98% | 5,742 |
| 24-04-17 | 5.585 | +1.36% | 13,949 |
| 24-04-16 | 5.51 | -2.82% | 12,620 |
| 24-04-15 | 5.67 | -1.22% | 5,248 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.65
USD
Average target price
23.1
USD
Spread / Average Target
+308.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.07% | 33.91M | |
| +72.65% | 12.34B | |
| -19.41% | 7.85B | |
| +14.98% | 7.13B | |
| -5.13% | 5.31B | |
| +5.78% | 5B | |
| +17.02% | 4.18B | |
| -25.36% | 3.76B | |
| -40.56% | 2.24B | |
| -3.47% | 1.93B |
- Stock Market
- Equities
- ECOR Stock
